RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 11:58 AM
Followers: 439
Posts Today: 13
Views Today: 27584

CYDY Stock Quote & Tools

$0.2005 ▲ +0.0005 (+0.25%) As of Oct 15, 12:37 PM EDT
Last0.2005
$ Chg0.0005
Open0.2000
High0.2090
Beta1.4964
Year High0.397
Market Cap294.64M
P/B Ratio-2.68
EPS-0.04
Avg Vol (30d)1.53M
Volume2.04M
% Chg+0.25%
Prev Close0.2000
Low0.1971
VWAP0.20082
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

3 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
  1. CDiddy

    I'm not aware of any results from lenzi

  2. sean007

    Thanks for the clarification Doctor....It has been my understanding that severe to critical was the

  3. Boatbuilder

    Just announced, UK on a new, nationwide lockdown. I imagine they too are awaiting CD12 results.

    (1)
  4. swordman

    drug trials during covid this should 100% apply to CYDY issues

    (1)
  5. ohm20

    One thing that's interesting is that as inflammation increases the level of GM-CSF decreases

    (4)
  6. Riztheinvestor

    Ive looked at lenzilumab much more closely. I think this is overlooked pretty often. It is a

  7. Dr Zaius

    New WSJ story on long haulers

    (2)
  8. JLang

    Somewhat (stock twits)... I think the larger issue is that the intersection of biology and finance

    (8)
  9. mtruong34

    Here is a recent publication on cytokine storms which references Dr. BP's paper and the eIND

    (4)
  10. CTMedic

    Jlang, Agreed, but why the recognition and falling price now? Ohms sharing the difficult truth

  11. Borel Fields

    Help, please, re: leron/lenzi comparison I think I remember Patterson saying something like only

    (1)
  12. ohm20

    That drug would have the same effect on mTORc1 as leronlimab. The inhibition of mTORc1 controls a

    (5)
  13. onestepahead

    https://www.ndtv.com/world-news/vaccines-may-not-work-on-south-african-covid-variant-say-uk-scienti

    (1)
  14. dfwl28

    ohms message on stocktwits 09:15 AM @Darronm HGEN's lenzilumab is a GM-CSF inhibitor, CYDY's

    (1)
  15. mtruong34

    The main reason for the reminder was to include the CORRECTION of the eIND exclusion criteria at

    (2)
  16. Evil Rabbit

    What are we supposed to do? Buy more? I, for one, am all-in. Maybe change your heading to

    (3)
  17. ohm20

    Lenzulimab has effect. With their exclusion criteria and primary endpoint being time to improvement

    (1)
  18. ohm20

    Their investors heard about leronlimab. :)

    (5)
  19. stockGuru2020

    SA ARTICLE IGNORED BY CYDY LONGS -

    (1)
  20. jeff67

    I think the main reason they sent the reminder out was to clarify the EUA comment. lawyers probably

  21. PersianLeo

    CT, S&P500 is down 5% today! One should wonder why CYDY is not affected (which BTW we know why

    (2)
  22. JLang

    Because HGEN's drug doesn't work?

    (3)
  23. thriftycents

    ohm's reply on stock twits comparing their drug's MOA vs. Leronlimab?

    (4)
  24. CTMedic

    Any thought on why humanigen stock getting hammered?

  25. MD VIROLOGIST

    I am assuming exclusion criteria are the same and therefore there is no data on the patients

  26. SmileyRiley

    $CYDY

    (11)
  27. ClosetInvestor

    Importantly, it now excludes patients with severe pulmonary injury (low ration of atrial oxygen

    (1)
  28. ohm20

    Must have ran it past the lawyers.

    (1)
  29. Dr Zaius

    In addition to the eIND criteria correction, subtle changes were made to the call agenda. Here is

    (12)
  30. mtruong34

    Yes Ohm. I noticed that too. Wouldn't it have been infinitely simpler to just say eIND is exactly

    (1)
  31. CTMedic

    It is stated a bit oddly, but the previous criteria were nonsensical leading to lots of confusion

    (1)
  32. Shelly2626

    Thank you for the clarification !!! GLTA

  33. CTMedic

    Todays PR was also the important clarification of the exclusion criteria for eIND & open label

    (1)
  34. ohm20

    That correction is stated very oddly. It's the same as our clinical trial just with the symbols

    (1)
  35. Borel Fields

    Leronlimab's supply from Samsung is a huge advantage. The Merck/ OncoImmune "fusion protein" (now

    (2)
  36. Shelly2626

    looks like a reminder to me ......already tweeted it to couple dozen people i know that are

  37. Shopcop7

    Can anyone make sense of todays PR, clearly its more than just a reminder, but at least to me, its

  38. SporadicE

    mechanically ventilated with PEEP >=15 cmH20 with Pa02/FiO2

    (25)
  39. Rubraquercus

    classic marx brothers news release(s). Unreal

    (2)
  40. Borel Fields

    Not a doc, but both now exclude the sickest. Was a typo, < vs, >, on first term. Exclusions:

    (2)
  41. JLang

    Vaccines' effectiveness in South African variant still in question, "substantial" changes in spike

    (1)
  42. mtruong34

    I'm not a doctor but Dr. Yo was recently complaining about the exclusion criteria having a direct

    (1)
  43. CaptnAmerca

    Can one of our esteemed doctors on the board explain what this is, and what it means? Thank

    (1)
  44. ohm20

    We can say those people were saved because COVID-19 did not kill them

  45. ohm20

    That would be an interesting long term, large population trial. 20,000 people on leronlimab, 20,000

  46. mtruong34

    It was to correct a gross error with the eIND PR regarding the exclusion

  47. onestepahead

    https://news.yahoo.com/mexican-doctor-hospitalized-receiving-covid-165419708.html

    (1)
  48. lorbas

    Good catch! In case someone missed it: "Correction: In a press release dated December 30,

    (1)
  49. Longestyard

    If I were on the verge of expiration I would consider 4 additional years very life

    (2)
  50. Longestyard

    Probably just trying to stay active on the comms, may see action from Cytodyn increase as readouts

Top 10 Most Recent News Articles

More News Articles

Top 5 Most Recently Viewed Articles

Toll Brothers Launches Exciting New Home Collections

Updated Category News Views 236

Toll Brothers Introduces New Luxury Home Collections Toll Brothers, Inc. (NASDAQ: TOL), the premier builder of luxury homes in the United States, is thrilled to announce the introduction of three unique collections of homes in the Eldorado neighborhood of Santa Rita Ranch. This community has rapidly become a sought-after destination for those seeking a blend of...

Continue Reading
Neonode Welcomes New Director to Its Leadership Team

Updated Category News Views 139

Neonode Strengthens Board with New Leadership Neonode Inc. (NASDAQ: NEON) has officially announced a significant change in its Board of Directors, focusing on the ongoing commitment to innovation and strategic growth. The company has appointed Didier Schreiber as a Class I Director, a decision reflecting its vision to drive forward in today's competitive market. This...

Continue Reading
Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 112

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Understanding Canada's Growing Credit Market and Gen Z's Role

Updated Category News Views 195

Insights into Canada's Expanding Credit Market The Canadian credit market has recently crossed a significant milestone, reaching $2.5 trillion in outstanding balances. This growth is notably marked by the active participation of younger consumers, particularly those from Generation Z. According to recent data, Gen Z Canadians contributed to 10% of the overall credit...

Continue Reading
Kaltura's Financial Call for First Quarter: What to Expect

Updated Category News Views 135

Kaltura's Upcoming Financial Results Announcement Kaltura (NASDAQ: KLTR), a trailblazer in the Video Experience Cloud sector, is poised to unveil its financial results for the first quarter. The announcement is anticipated to occur before the market opens on an exciting Thursday in May. As a company known for its commitment to innovation in video technology, this...

Continue Reading